Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMarks Electric Share News (MRK)

Share Price Information for Marks Electric (MRK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 67.50
Bid: 66.00
Ask: 69.00
Change: 0.00 (0.00%)
Spread: 3.00 (4.545%)
Open: 67.50
High: 67.50
Low: 67.50
Prev. Close: 67.50
MRK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Canaccord Genuity lowers target price on Marks Electrical

Wed, 10th Jan 2024 09:21

(Sharecast News) - Analysts at Canaccord Genuity lowered their target price on online retailer Marks Electrical from 123.0p to 100.0p on Wednesday, citing short-term product margin pressure.

Canaccord Genuity noted that Marks Electrical's recent trading update had outlined strong top-line growth of roughly 17.8% for Q3 and 22% year-to-date, slightly stronger than its expectations. However, it also pointed out that despite the "strong top-line growth", gross product margins had disappointed, negatively impacted by a continued drop in consumer trading, against a strong comparative in the first half.

As a result, management now expects full-year revenues of between £115.0m-118.0m and underlying earnings between £5.0m-6.0m.

"Following today's update, we maintain revenue estimates but downgrade our FY24E and FY25E EBITDA estimates by 38% and 28%, respectively. While today's update is disappointing, we believe it reflects short-term macroeconomic headwinds that are outside of management's control, while the business continues to take market share and maintain excellent customer service and cost discipline," said Canaccord.

The Canadian bank, which reiterated its 'buy' rating on the stock, also believes the long-term story for Marks "remains intact", yet, short-term, the shares were likely to "see pressure" given the "sizeable downgrades".

Reporting by Iain Gilbert at Sharecast.com

More News
20 Mar 2018 07:05

UPDATE 1-Roche says Tecentriq, chemo cut risk of death in type of lung cancer

ZURICH, March 20 (Reuters) - Roche's immunotherapy Tecentriq plus chemotherapy cut the risk of disease worsening or death in advanced squamous lung cancer, but it did not

Read more
8 Mar 2018 02:05

UPDATE 3-Eisai clinches Merck deal to develop and sell cancer drug, shares soar

* Deal could be worth up to $5.76 billion to Eisai * Eisai's drug Lenvima already approved in dozens of countries * Lenvima sales could top $1 bln 8

Read more
7 Mar 2018 22:16

Merck, Eisai sign deal to further develop, sell Eisai cancer drug

March 7 (Reuters) - Merck & Co and Japan's Eisai Co Ltd on Wednesday announced a potential multibillion-dollar collaboration to develop and sell Eisai's cancer is

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.